Fibrocell Science Inc (NASDAQ:FCSC) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $5.70 target price on shares of Fibrocell Science in a research note on Friday, June 9th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Fibrocell Science currently has an average rating of “Buy” and an average price target of $3.36.

Fibrocell Science (FCSC) traded down 1.80% during mid-day trading on Thursday, hitting $3.82. The stock had a trading volume of 24,772 shares. The company has a 50-day moving average price of $3.36 and a 200 day moving average price of $1.97. The company’s market cap is $56.13 million. Fibrocell Science has a 1-year low of $1.57 and a 1-year high of $4.64.

Fibrocell Science (NASDAQ:FCSC) last announced its earnings results on Wednesday, May 10th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.29. Fibrocell Science had a negative return on equity of 236.55% and a negative net margin of 4,307.60%. Equities research analysts forecast that Fibrocell Science will post ($1.39) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Fibrocell Science Inc (FCSC) Upgraded by ValuEngine to “Hold”” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/20/fibrocell-science-inc-fcsc-upgraded-by-valuengine-to-hold.html.

Institutional investors have recently made changes to their positions in the company. Creative Planning raised its position in shares of Fibrocell Science by 395.3% in the second quarter. Creative Planning now owns 61,090 shares of the company’s stock worth $245,000 after buying an additional 48,755 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Fibrocell Science by 272.4% in the fourth quarter. Renaissance Technologies LLC now owns 194,000 shares of the company’s stock valued at $122,000 after buying an additional 141,900 shares during the period. Third Security LLC acquired a new stake in shares of Fibrocell Science during the fourth quarter valued at approximately $10,470,000. Oxford Asset Management boosted its stake in shares of Fibrocell Science by 60.2% in the second quarter. Oxford Asset Management now owns 313,959 shares of the company’s stock valued at $361,000 after buying an additional 118,007 shares during the period. Finally, Janney Montgomery Scott LLC boosted its stake in shares of Fibrocell Science by 54.6% in the second quarter. Janney Montgomery Scott LLC now owns 172,932 shares of the company’s stock valued at $199,000 after buying an additional 61,050 shares during the period. 54.97% of the stock is owned by hedge funds and other institutional investors.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.